Both quantitative measures for ER alone provided additional discrimination in breast cancer-specific mortality risk for white women but not black women with ER-positive tumors, while the ER/PR/HER2 score provided the additional discrimination for both white women and black women with ER-positive tumors. The gene discussed is PGR; the disease is breast carcinoma.